Novo's stock down 7% amid sales goal
Shares of Novo Nordisk fell by up to 7% following their announcement of growth ambitions in the obesity medication market, where they plan to launch more than five new drugs by 2030 and achieve sales exceeding $23 billion by 2035. Despite the company's insistence on its competitive capabilities in a increasingly crowded market, the response to the announcement was a decline, and growth forecasts between 2026 and 2030 remain in line with the sector.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)